Corporate, Commercial & Regulatory

Impressive depth of specialised experience

Van Bael & Bellis advises multinational clients on corporate, commercial and regulatory issues in the EU and Belgium.

Discover our expertise
  • "The lawyers are excellent; very responsive and to the point."

    Chambers Europe

Subscribe to our updates

Please select the practice areas you are interested in: *

Get in touch

Please fill out the form below along with your query and someone from the team will get back to you. Alternatively you can email [email protected]

Recommendations

  • The quality of the advice is great - we have been asking some complex questions and they have given clear and to-the-point advice and have been very proactive in providing alternative solutions.

    Chambers Europe
  • Van Bael & Bellis has ‘impressive knowledge of dispute resolution, including mediation’. The firm is notable for its strong regulatory and administrative law contentious practice as well as its impressive life sciences sector presence.

    Legal 500
  • They patiently try to understand the mentality of people in different cultures and pay full respect to that. This attitude is rare in a highly expert world. We are fully satisfied with their practice and the results therefrom.

    IFLR1000
  • They are very responsive, and experienced in pharma and compliance-related matters. They always indicate the timelines of the work they do and keep the client informed on the status of the work.

    Chambers Europe

Team focus

Van Bael & Bellis is well known for its client-centred approach, commitment to excellence, exceptional client service and personalised attention.

Get in touch with our Corporate, Commercial & Regulatory teams today

Recent publications

Sign up for updates
    • 20/07/2018
    • Articles

    Personal Data Transfers to Japan One Step Closer to Adequacy as EU and Japan Conclude Negotiations

    Data Protection | On 17 July 2018, the European Union and Japan successfully concluded their negotiations on reciprocal adequacy. These negotiations recognise Japan and the European Union as providing a comparable level of protection of personal data, and clear the way for a seamless transfer of personal data between Japan and the European Union.

    Read more
    • 20/07/2018
    • Articles

    European Medicines Agency Publishes First Report on Implementation of Clinical Data Publication Policy

    Life Sciences | The European Medicines Agency (“EMA”) published on 16 July 2018 its first report on the implementation of its policy on the publication of clinical data (see attached). The report covers one year following the launch of EMA’s clinical data website on 20 October 2016 and lists the 50 medicines for which clinical data were published, including orphan, paediatric, biosimilar and generic medicines, as well as the corresponding 54 regulatory dossiers.

    Read more
    • 18/07/2018
    • Articles

    EU and Japan Expand Collaboration on Inspection of Medicine Manufacturers

    Life Sciences | Today, the European Medicines Agency (“EMA”) and the European Commission both announced an agreement between the European Union (“EU”) and Japan to broaden the range of medicines for which both parties will recognise each other’s Good Manufacturing Practice inspections of manufacturing sites. The new agreement builds on a mutual recognition agreement (the “MRA”) that became operational in May 2004 and provides for various forms of cooperation with regard to medicines in addition to the reciprocal recognition of manufacturing inspections.

    Read more
Keep updated Sign up for VBB insights

Be the first amongst your peers to get the latest publications and insights in Corporate, Commercial & Regulatory law.